Faculty

Faculty Profiles

Ahmed El-Shamy, PhDAhmed El-Shamy, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: (916) 686-7300

Dr. Ahmed El-Shamy is an assistant professor of Virology at California Northstate University. In 2009, Dr. El-Shamy received a PhD in Molecular Virology from Kobe University, Japan. His PhD study was selected as the Medical School Excellent Paper for the 2008-2009 Academic Year. In 2011, Dr. El-Shamy joined Division of Liver Diseases at Mount Sinai School of Medicine, New York as a senior post-doctoral fellow. Dr. El-Shamy received 2014 Japan Society for the Promotion of Science (JSPS) Award; and 2013 Encouragement State Prize in Medical Sciences from the Academy of Scientific Research and Technology, Egypt. Dr. El-Shamy published 26 publications in high impact peer-viewed journal (https://www.ncbi.nlm.nih.gov/pubmed/?term=Ahmed+El-Shamy). Dr. El-Shamy is the lead author in 10 publications; three of them have been published in the highest journals of liver field (two in Hepatology and one in Journal of Hepatology).

Research Interest: Dr. El-Shamy’s research focuses on investigating the molecular biology underlying the intra- and extra-hepatic pathogenesis of viral hepatitis, including:

  1. Identifying novel Direct Acting Anti-viral molecule against Hepatitis B Virus (HBV), with special focus on eliminating HBV-cccDNA.
  2. Investigating the molecular mechanism underlying the clinical correlation between HBx mutations of HBV and development of liver cancer.
  3. Investigating the molecular mechanism underlying the dysregulation of lipid metabolism after successful cure of Hepatitis C Virus (HCV) by direct acting antiviral therapy (DAA).
  4. Investigating the correlation between HCV infection and B cells disorders, such as Type II Cryoglobulinemia

Course Taught: Advance Topics in Virology

Selected publications (From 26 papers; https://www.ncbi.nlm.nih.gov/pubmed/?term=Ahmed+El-Shamy):

  1. Eng FJ, El-Shamy A, Doyle EH, Klepper AL, Muerhoff S, Branch AD. Newly-discovered Hepatitis C Virus Minicores Circulate in Human Blood. Hepatology Communications. 2017 Nov 12;2(1):21-28.
  2. El-Shamy A, Pendleton M, Eng F, Doyle E, Bashir A and Branch A. Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients. Scientific Reports. 2016; 6:27025. doi: 10.1038/srep27025.
  3. El-Shamy A, Eng FJ, Doyle EH, Klepper AL, Sun X, Sangiovanni A, Iavarone M, Colombo M, Schwartz RE, Hoshida Y, Branch AD. A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene. J Hepatol. 2015 Dec;63(6):1323-33.
  4. El-Shamy A, Hotta H. Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. World J Gastroenterol. 2014 Jun 28;20(24):7555-69.
  5. El-Shamy A, Shindo M, Shoji I, Deng L, Okuno T, Hotta H. Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma. Hepatology. 2013 Aug;58(2):555-63.
  6. El-Shamy A, Shoji I, El-Akel W, Bilasy SE, Deng L, El-Raziky M, Jiang DP, Esmat G, Hotta H. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol. 2012 Dec;50(12):3886-92.
  7. Kim SR, El-Shamy A, Imoto S, Kim KI, Ide YH, Deng L, Shoji I, Tanaka Y, Hasegawa Y, Ota M, Hotta H. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load. J Gastroenterol. 2012 Oct;47(10):1143-51.
  8. El-Shamy A, Shoji I, Kim SR, Ide Y, Imoto S, Deng L, Yoon S, Fujisawa T, Tani S, Yano Y, Seo Y, Azuma T, Hotta H. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy. PLoS One. 2012;7(2):e30513.
  9. El-Shamy A, Kim SR, Ide YH, Sasase N, Imoto S, Deng L, Shoji I, Hotta H. Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated interferon/ribavirin combination therapy. Intervirology. 2012;55(1):1-11.
  10. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology. 2008 Jul;48(1):38-47.
  11. El-Shamy A, Sasayama M, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera. Microbiol Immunol. 2007;51(4):471-82.

Catherine F. Yang, PhDCatherine F. Yang, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: (916) 686-7300

Dr. Yang is a Professor of Molecular Pharmacology at the Department of Basic Science of College of Medicine of California Northstate University (CNU). Before joining CNU, Dr. Yang was a biochemistry/pharmacology Professor in the Department of Chemistry and Biochemistry at Rowan University for 23 years. She also held Professorships at Cooper Medical School of Rowan University in the Departments of Chemistry and Biochemistry and Translational Biomedical Sciences. While at Rowan, Dr. Yang served as the Chairperson for the Department of Chemistry and Biochemistry from 2007 to 2016 and the Director for the Biochemistry Program from 2000 to 2007. She has held research and faculty positions at Harvard Medical School, the American Health Foundation, Boston Biomedical Research Institute, Tokyo University of Medicine and Dentistry, University of Pennsylvania and Zhejiang University of Technology.

Dr. Yang has made strong contributions in elucidating mechanisms of tumor progression, and in the development of novel cancer drugs and antibiotics. She has led research groups studying proteolytic regulatory mechanisms in the advanced stages of prostate cancer, lung cancer and leukemia. Her in-depth research on type 2 diabetic metabolic regulation led to a dual function diabetes drug patent. Dr. Yang’s immunological research resulted in an allergy vaccine development that is currently under clinical trials at affiliated clinics. The specific approach of triggering induction of immunologic tolerance to external or autologous allergens, and induction of sensitization to infectious or tumor antigens, with targeted tissue delivery of particles sized to facilitate uptake by specific cell populations, will provide unique therapeutic platform for curing advancement stage cancer. Dr. Yang’s unique predictive biomarker studies have also spurred a nano-sensor development for an early cancer diagnosis.

Dr. Yang has published more than 60 research papers, several biotechnology books, and is an inventor of several patented inventions. She has also secured numerous grants from the NIH, NSF, Research Corporation and New Jersey Health Foundation as well as funding from many corporations and health foundations. She serves on various review boards of federal, private and health foundation funding agencies.

Research Interests: Dr. Yang research interest centers around the proteolytic regulation in various disease progression stages including aging. Her drug discovery programs specifically target against type 2 diabetes, prostate cancer, leukemia and lung cancer. Her current interest in developing allergy vaccines has been resulted in clinical trials at affiliated clinics.

Selected publications:

  1. Yang, C. F., LI, W., ELLIOTT, R. and Iltchenko, Ni., “Extraction And Purification Of Urushiol From Botanical Sources”, US, Patent, 9,580,373 B2, February 28, 2017.
  2. Lizza, J. R., Patel, S. V., Yang, C. F. and Moura-Letts, G., “Direct Synthesis of Cyanopyrrolidinyl b-Amino Alcohols for the Development of Diabetes Therapeutics”, Eur J Organic Chemistry, 2016, 5160-5168.
  3. Yin, A.C., Goldberg, K.H., Mupparapu, A., Retzbach, E. P., Yin, K., Yang, C. F. and Goldberg, G. S., “Low Molecular Weight Components in Aqueous Echinacea Purpurea Leaf Extract Inhibit Melanoma Cell Growth”, J. Cancer Biology and Therapeutics, 2016, 1(2): 109-117.
  4. Goldberg, K. H., Yin, A.C. Mupparapu, A., Retzbach, E., Goldberg, G. and Yang, C. F., “Components in aquesou Hibiscu rosa-sinensis flower extract inhibit in vitro melanoma cell growth”, J. Trad. Comp. Medicine, 2016, 7(1): 45-49.
  5. Coifman, R. and Yang, C. F., “Method of Depositing Particles of a Substance in a Tissue”, US Patent, US 2015/0140040 A1, May 21, 2015.
  6. Yang, C. F. and Li, W. X, “Novel Dipeptidyl Peptidases IV-based Inhibitors for Type 2 Diabetes Complex with Hypertension”, US, Patent, 9,115,082 B2, Aug. 25, 2015, PCT/US14/12180, 2015.
  7. Yang, C. F., book, “Experiments in Biochemistry and Biotechnology” by Cengage Learning, 2013.
  8. Coifman, R., Yang, C. and Kloske, S., “New Generation of the Poison Ivy Vaccine in Clinical Study”, Garden State Focus, April, 2014, 20, 4, 11-13 (featured on cover page).
  9. Hu, X., Duki, S., Forys, J., Hettinger, J., Buchicchio, J., Dobbins, T. and Yang, C., “Designing Silk-Silk Protein Alloy Materials for Biomedical Applications”, J. Visualized Experiments, 2014
  10. Kojtari, A., Shah, V., Babinec, J.; Yang, C.; Ji, H-F., “Structure-Based Drug Design of Diphenyl α- Aminoalkylphosphonates as Prostate-Specific Antigen Antagonists”, J. of Chem. Information and Modeling, 2014, 54 (10), 2967-2979.
  11. Kojtari, A, Ji, H-F and Yang, C.F. “Aminoalkylphosphoate Derivatives Inhibitors for Prostate Cancer Target”, Provisional US Patent, 13-1627D, 2013, PCT/US15/046528-7014WO(00564).
  12. J. P. Lin and F. Yang, “Recent Advances in Micro/nano- particales for clinical detection of cancer biomarker”, review, Analytical Methods, 2013, 5(21), 5839-6248. (featured on cover page)
  13. Yang, C.F., Zakreski, R., Li, W., Mou, X., Iltchenco, N. and Cooperman, B., “Proteolytic Inhibition in Regulating the Insulin-like Binding Proteins in Prostate Cancer”, Biochem & Physiol., 1(2), 1-8, 2012.
  14. Sun, Y., Yang, C.F. and Li, W., “PROCESS FOR THE PREPARATION OF ERLOTINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS”, US, Patent application #, 61,595,925, 2012.
  15. J. P. Lin, S. H. Li and F. Yang, “Electrochemical Sensors for Cancer Biomarker Detection”, Review, Electroanalysis, 24, 12, 2213-2229, 2012.
  16. Jao, D, Duda, T., Gillespie, A., Yu*, L. and Yang,* C., “Direct Determination of Gold Nanoparticle in Biomacromolecular Matrix with Flame Atomic Absorption Spectrophotometry”, Journal of Nanomedicine and Biotherapeutic Discovery, 2011, 1, 1-5.
  17. Velusamy, V., Arshak, K., Yang, F. C., Korostynska, O. and Adley, C., “Comparison Between DNA Immobilization Techniques on a Redox Polymer Matrix”, Am. J. Ana. Chem., 2011, 2, 392-400.
  18. Wang, H., Xu, X., Li, L., Yang, C. and Ji, H-F., “Optoelectronic property and sensing applications of crystalline nano/microwires of decacyclene”, Micro & Nano Letters, 2011, 6, 9, 763-766.

Simeon Kotchoni, PhDSimeon Kotchoni, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: (916) 686-7690
Fax: (916) 686-8142

Research Interest: Dr. Kotchoni is an associate professor in the Department of Pharmaceutical and Biomedical Sciences at California Northstate University, College of Pharmacy (CNUCOP). Prior to joining CNUCOP, he was an assistant Professor at Rutgers University, Camden, New Jersey (2011-2017). He received his B.S. and MS in Biochemistry and Cell Biology from University of Abomey Calavi, Benin, and another MS in Microbiology from Obafemi Awolowo University, Ile-Ife, Nigeria. He received his Ph.D. from the University of Bonn, Germany, where he study the role of Aldehyde Dehydrogenase (ALDH) Gene superfamily in a model plant, Arabidopsis thaliana. After his Ph.D., Dr. Kotchoni has worked as a postdoctoral researcher in Europe (Bonn, Germany), and USA (West Virginia University and Purdue University), using interdisciplinary research techniques, including molecular genetics, cell biology, proteomics, transcriptomics, metabolomics to understand the molecular and cellular mechanisms of growth development and environmental adaptation of organisms.

The Kotchoni laboratory studies health benefits of natural products, especially, medicinal plants, and micororganisms. We focus on understanding the molecular and clinical effects of natural-derived compounds on chronic diseases and developing botanical therapeutics for health promotion and wellness. Our work extends to worldwide research collaborations on drug discovery and development. Drug discovery from natural products represents a re-visited area of active interest. In a multi-disciplinary investigator collaboration, our laboratory is currently developing small molecules from natural products against diabetes, Hepatitis B Virus, prostate, brain, breast and colon cancers with limited or no side effects.

Courses taught: Aromatherapy and Techniques in Metabolomics

Selected Publications (from 104 papers: https://www.researchgate.net/profile/Simeon_Kotchoni)

  1. Missihoun TD, Kotchoni SO., Bartels D. Aldehyde Dehydrogenases Function in the Homeostasis of Pyridine Nucleotides in Arabidopsis thaliana. Nature, Scientific Reports. 2018, 8: 2936. DOI:10.1038/s41598-018-21202-6.
  2. Missihoun TD, Kotchoni SO. Aldehyde dehydrogenases may modulate signaling by lipid peroxidation-derived bioactive aldehydes. Plant Signaling and Behavior. 2017; 12(11): e1387707.
  3. Kotchoni SO., Kibiti C., Gachomo B., Jimenez-Lopez J.C., Martin J.V., Emergence of Herbal Medicine as a New Trend in Pharmacological Management of Diabetes Mellitus. In: Recent Progress in Medicinal Plants. 2017; Chapter 9, pp: 171-188.
  4. Sakirigui A., Gbaguidi F, Kasséhin U.C., Poupaert J., Accrombessi G.C., Kotchoni S.O. Structural and antitrypanosomal data of different carbasones of piperitone. Data in Brief. 2016; 9: 1039-1043.
  5. Kotchoni SO, Gachomo EW, Slobodenko K, Shain DH. AMP DEAMINASE suppression increases biomass, cold tolerance and oil content in green algae. Algal Research. 2016; 16: 473-480.
  6. Missihoun T.D., Kotchoni S.O., Bartels, D. Active site of REDUCED EPIDERMAL FLUORESCENCE 1 (REF1) isoforms contain amino acid substitutions that are different between monocots and dicots. PLOS ONE. 2016; 11(10): e0165867.
  7. Glinma B, Kpoviessi SD, Gbaguidi FA, Kapanda CN, Bero J, Quetin-Leclercq J, Moudachirou M, Poupaert J, Accrombessi GC, Gachomo EW, Baba-Moussa L, Kotchoni SO. Trypanocidal and cytotoxic evaluation of synthesized thiosemicarbazones as potential drug leads against sleeping sickness. Molecular Biology Reports. 2014; 41(3): 1617-1622.
  8. Jimenez-Lopez JC, Wang X, Kotchoni SO, Huang S, Szymanski DB, Staiger CJ., Heterodimeric capping protein from Arabidopsis is membrane-associated, actin-binding protein. Plant Physiology. 2014; 166: 1312-1328.
  9. Gbenou J. D., Ahounou J.F., Akakpo H. B., Yayi E., Laleye A., Gbaguidi F., Baba-Moussa L., Darboux R., Dansou P., Moudachirou M., Kotchoni S.O. Phytochemical composition of Cymbopogon citratus and Eucalyptus citriodora essential oils and their anti-inflammatory and analgesic properties on Wistar rats. Molecular Biology Reports. 2013; 40(2): 1127-1134.
  10. Jimenez-Lopez JC, Kotchoni SO, Hernandez-Soriano MC, Gachomo EW, Alché JD. Structural functionality, catalytic mechanism modeling and molecular allergenicity of phenylcoumaran benzylic ether reductase, an olive pollen (Ole e 12) allergen. Journal of Computational Aided Molecular Design. 2013; 27: 873-895.
  11. Jimenez-Lopez J.C., Gachomo E.W., Ariyo O.A., Baba-Moussa L., Kotchoni S.O. Specific conformational epitope features of pathogenesis-related proteins mediating cross-reactivity between pollen and food allergens. Molecular Biology Reports. 2012; 39(1): 123-130.
  12. Jimenez-Lopez J.C., Kotchoni S.O., Rodríguez-García M.I., Alché J.D. Structure and functional features of olive pollen pectin methylesterase using homology modeling and molecular docking methods. Journal of Molecular Modeling. 2012; 18(12): 4965-4984
  13. Jimenez-Lopez J.C., Gachomo E.W., Ariyo O.A., Baba-Moussa L. and Kotchoni S.O. Specific conformational epitope features of pathogenesis-related proteins mediating cross-reactivity between pollen and food allergens. Molecular Biology Reports. 2012; 39(1): 123-130.
  14. Baba-Moussa L., Sina H., Scheftel J.M., Moreau B., Sainte-Marie D., Kotchoni S.O., Prévost G., Couppié P. Staphylococcal Panton-Valentine leucocidin as a major virulence factor associated to furuncles. PLoS One. 2011; 6(10): e25716.
  15. Kotchoni S.O., Jimenez-Lopez J.C., Gachomo E.W. Seufferheld M.J., A new and unified nomenclature for male fertility restorer (RF) proteins in higher plants. PLOS ONE. 2010; 5(12): e15906.
  16. Zhang C., Kotchoni S.O., Samuels L., Szymanski D.B., SPIKE1 signals originate from and assemble specialized domains of the endoplasmic reticulum. Current Biology. 2010; 20(23): 2144-2149.
  17. Kotchoni S.O., Zakharova T., Mallery E.L., El-Din El-Assal S., Le J., Szymanski D.B., The association of the Arabidopsis actin-related protein (ARP) 2/3 complex with cell membranes is linked to its assembly status, but not to its activation. Plant Physiology. 2009; 151(4): 2095-2109.

Hongbin Wang, PharmBS, MS, PhDHongbin Wang, PharmBS, MS, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Telephone: (916) 686-8034
Fax: (916) 686-8142

Research Interest: Dr. Hongbin Wang is an Assistant Professor in the Department of Pharmaceutical and Biomedical Sciences at the California Northstate University College of Pharmacy. Before joining CNUCOP, he worked as a Senior Research Investigator in the Department of Pathology & Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine. He received his B. Med. (Pharmacy) and M. Med. (Pharmacology) from Second Military Medical University (Shanghai, China), and his Ph.D. in Pharmacology from University of Pennsylvania.

His primary research interests include studying: 1), interaction of complement activation fragment C4a with protease-activated receptor (PAR) 1/4 G-protein coupled receptors and their roles and signaling pathways in the initiation and progress of sepsis, diabetes mellitus, and autoimmune diseases. 2), the function and regulation of protein kinase C isozymes (PKCs), the receptors for the phorbol ester tumor promoters and the second messenger diacylglycerol (DAG), an important intracellular mediator of proliferation and malignant transformation. 3), the “chimaerins”, novel phorbol ester/DAG receptors with Rac-GAP activity toward Rac that is a small GTP-binding protein that regulates actin cytoskeleton organization, cell cycle progression, gene expression, cell adhesion and migration.

Publications (selected from 44 papers):

  1. Wang H, Daniel Ricklin, and John D. Lambris. Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proc Natl Acad Sci U S A. 2017; 114(41): 10948-10953. PMID: 28973891
  2. Wang H, Gutierrez-Uzquiza A, Garg R, Barrio-Real L, Abera MB, Lopez-Haber C, Rosemblit C, Lu H, Abba M, Kazanietz MG. Transcriptional Regulation of Oncogenic Protein Kinase C Epsilon (PKCe) by Stat1 and Sp1. J Biol Chem. 2014; 289(28): 19823-38. PMID: 24825907
  3. Wang H*, Xiao L and Kazanietz MG*. Tmp21/p23, an ER/Golgi cargo protein, regulates phorbol ester-induced apoptosis in LNCaP prostate cancer cells via direct association with PKCd. J Biol Chem. 2011; 286:15821-15831. PMID: 21454541. (*Corresponding author).
  4. Wang H, Kazanietz MG. p23/Tmp21 differentially targets the Rac-GAP beta2-chimaerin and protein kinase C via their C1 domains. Mol Biol Cell. 2010; 21:1398-1408. PMID: 20164256
  5. Wang H, Yang C, Leskow FC, Sun J, Canagarajah B, Hurley JH, and Kazanietz MG. Phospholipase Cg/Diacylglycerol-dependent Activation of b2-Chimaerin Restricts EGF-Induced Rac Signaling. EMBO J. 2006; 25: 2062-2074. PMID: 16628218
  6. Wang H, and Kazanietz MG. The lipid second messenger diacylglycerol as a negative regulator of Rac signaling. Biochem Soc Trans. 2006; 34: 860-862. PMID: 17052214
  7. Caloca MJ*, Wang H*, Kazanietz MG. Characterization of the Rac-GAP (Rac-GTPase-activating protein) activity of beta2-chimaerin, a ‘non-protein kinase C’ phorbol ester receptor. Biochem J. 2003; 375: 313-321 (* Equal contribution). PMID: 12877655
  8. Wang H, Kazanietz MG. Chimaerins, novel non-protein kinase C phorbol ester receptors, associate with Tmp21-I (p23): evidence for a novel anchoring mechanism involving the chimaerin C1 domain. J Biol Chem. 2002; 277: 4541-4550. PMID: 1168955
  9. Rachana Garg, Lorena Benedetti, Mahlet Abera, HongBin Wang, Martin Abba, and Marcelo Kazanietz. Protein kinase C and cancer: what we know and what we do not. Oncogene 2013; PMID: 24336328
  10. Oxana M. Tsygankova, HongBin Wang, and Judy L. Meinkoth. RAP1GAP regulates tumor cell migration and invasion. J Biol Chem. 2013; 288:24636-46. PMID: 23864657
  11. Alvaro Gutierrez-Uzquiza, Francheska Colon-Gonzalez, Thomas A. Leonard, Bertram J. Canagarajah, HongBin Wang, Bruce J. Mayer, James H. Hurley, and Marcelo G. Kazanietz. Coordinated activation of the Rac-GAP (b2-chimaerin) by an atypical proline-rich domain and diacylglycerol. Nature Commun. 2013; 4:1849. PMID: 23673634
  12. Garg R, Blando J, Perez CJ, Wang H, Benavides FJ, Kazanietz MG. Activation of Nuclear Factor-Kappa B (NFκB) in Prostate Cancer is Mediated by PKC Epsilon (PKC{epsilon}). J. Biol. Chem. 2012; 287:37570-82. PMID: 22955280
  13. Riccomagno MM, Hurtado A, Wang H, Macopson JG, Griner EM, Betz A, Brose N, Kazanietz MG, Kolodkin AL. The RacGAP β2-Chimaerin selectively mediates axonal pruning in the hippocampus. Cell. 2012; 149:1594-606. PMID: 22726444
  14. Maria Soledad Sosa, Cynthia Lopez-Haber, Chengfeng Yang, Hongbin Wang, Mark A. Lemmon, John M. Busillo, Jiansong Luo, Jeffrey L. Benovic, Andres Klein-Szanto, Hiroshi Yagi, J. Silvio Gutkind, Ramon E. Parsons, and Marcelo G. Kazanietz. Identification of the Rac-GEF-P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol Cell. 2010; 40:877-892. PMID: 21172654
  15. Oxana M. Tsygankova, Gregory V. Prendergast, Kanchan Puttaswamy, Yan Wang, Michael D. Feldman, Hongbin Wang, Marcia S. Brose and Judy L. Meinkoth. Downregulation of Rap1GAP contributes to Ras transformation. Mol. Cell. Biol. 2007; 27: 6647-6658. PMID: 17646383
  16. Leskow FC, Holloway BA, Wang H, Mullins MC, Kazanietz MG. The zebrafish homologue of mammalian chimaerin Rac-GAPs is implicated in epiboly progression during development. Proc Natl Acad Sci U S A. 2006; 103: 5373-5378. PMID: 16569702
  17. Zhang Z, Kostetskii I, Moss SB, Jones BH, Ho C, Wang H, Kishida T, Gerton GL, Radice GL, Strauss JF 3rd. Haploinsufficiency for the murine orthologue of Chlamydomonas PF20 disrupts spermatogenesis. Proc Natl Acad Sci U S A. 2004; 101: 12946-12951. PMID: 15328412

Zhuqiu (James) Jin, PhDZhuqiu (James) Jin, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: (916) 686-7690

Dr. Zhuqiu Jin is an Associate Professor in the Department of Pharmaceutical & Biomedical Sciences at the California Northstate University College of Pharmacy. He obtained his M.S. degree in Pharmacology from Shenyang Pharmaceutical University and a Ph.D. degree in Pharmacology from Central South University. Dr. Jin was a postdoctoral scholar at the University of California, San Francisco exploring the effects of sphingolipids in cardioprotection. Prior to joining California Northstate University, Dr. Jin taught Pharmacology for Pharm.D. students and Ph.D. graduate students and carried out cardiovascular research as a faculty member at South Dakota State University.

The original contribution in Dr. Jin’s research is related to sphingosine 1-phosphate (S1P)-induced cardioprotection against myocardial ischemia/reperfusion injury and S1P-mediated ischemic preconditioning and postconditioning. These results were published in Circulation, Am J Physiol, Cardiovascular Research, etc. S1P has been recognized as one of the key triggers and mediators in cardioprotection. By using genetic and pharmacological approaches, Dr. Jin and his team unraveled the crucial role of T cell S1P receptors (S1P1) in diabetic cardiomyopathy. Specific deletion of T cell S1P1 protects diabetic hearts from cardiac fibrosis. The cross-talk between T cells and cardiac myocytes may provide a new strategy to protect hearts.

Research Interest: Dr. Jin’s research interest is focused on sphingolipid signaling pathway in cardiac fibrosis and remodeling. To uncover the cross-talk between immune cells and cardiac myocytes or fibroblasts in myocardial injury is the major field that Dr. Zhuqiu Jin is exploring.

Course taught: Techniques in Pharmaceutical Sciences

Selected publications:

  1. Abdullah CS, Li Z, Wang X, Jin ZQ. Depletion of T lymphocytes ameliorates cardiac fibrosis in streptozotocin-induced diabetic cardiomyopathy. Int Immunopharmacol. 2016; 39: 251-264.
  2. Li Z, Abdullah CS, Jin ZQ. Inhibition of PKC-θ preserves cardiac function and reduces fibrosis in streptozotocin-induced diabetic cardiomyopathy. Br J Pharmacol. 2014; 171: 2913-2924.
  3. Lovett DH, Mahimkar R, Raffai RL, Cape L, Zhu BQ, Jin ZQ, Baker AJ, Karliner JS. N-Terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure. PLoS ONE 2013; 8: e68154.
  4. Li Z, Jin ZQ. Ischemic preconditioning enhances integrity of coronary endothelial tight junctions. Biochem Biophy Res Commun. 2012 425: 630-635.
  5. Bandhuvula P, Honbo N, Wang G, Jin ZQ, Fyrst H, Zhang M, et al. S1P lyase (SPL): a novel therapeutic target for ischemia/reperfusion injury of the heart. Am J Physiol. Heart Cir Physiol. 2011; 300: H1753-H1761.
  6. Vessey DA, Li L, Jin ZQ, Kelley M, Honbo N, Zhang J, Karliner JS. A sphingosine kinase for 2 knockout sensitizes mouse myocardium to ischemia/reperfusion injury and diminishes responsiveness to ischemic preconditioning. Oxidative Medicine & Cellular Longevity. 2011; Article ID: 961059.
  7. Jin ZQ, Karliner JS, Vessey DA. Ischemic postconditioning protects isolated mouse hearts against ischemia/reperfusion injury via sphingosine kinase isoform 1 activation. Cardiovasc Res. 2008; 79: 134-140.
  8. Jin ZQ, Zhang J, Huang Y, Hoover HE, Vessey DA, Karliner JS. A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc Res. 2007; 76: 41-50.
  9. Jin ZQ, Karliner JS. N, N-Dimethylsphinjgosine is cardioprotective and activates cytosolic sphingosine kinase by a PKCε dependent mechanism. Cardiovasc Res. 2006; 71: 725-734.
  10. Jin ZQ, Zhou HZ, Cecchini G, Gray MO, Karliner JS. Manganese superoxide dismutase in mouse heart: acute responses to ischemic preconditioning and ischemia/reperfusion injury. Am J Physiol. Heart Cir Physiol. 2005; 288: H2986-H2994.
  11. Jin ZQ, Goetzl EJ, Karliner JS. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation 2004; 110: 1980-1989.

Ishwarlal Jialal, MD, PhDIshwarlal Jialal, MD, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: (916) 686-7300
Fax: (916) 686-7310

ISHWARLAL JIALAL graduated with the equivalent of an MD, PhD (MB.CH.B, MD) from the University of Natal Medical School, Natal, South Africa, and thereafter undertook fellowships at the Joslin Diabetes Center, Harvard Medical School, and in the Division of Endocrinology, Metabolism and Nutrition at the University of Washington in Seattle. He then joined the faculty of the University of Texas Southwestern Medical Center at Dallas in 1988 as Assistant Professor and became Professor of Internal Medicine and Pathology with tenure in 1997. He was Director of the Division of Clinical Biochemistry and Human Metabolism and was the first hold of the C. Vincent Prothro Chair in Human Nutrition Research. He then joined UC Davis Medical Center as the first holder of Robert E. Stowell Endowed Chair in Experimental Pathology, Director of the Laboratory for Atherosclerosis and Metabolic Research. On his retirement in 2016 he was Distinguished Professor of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, at the University of California, Davis, Medical Center and Staff Endocrinologist at the VA Medical Center, Sacramento.He is presently Professor of Physiology, Metabolism and Pathology at California Northstate university, College of Medicine and Staff Endocrinologist at the VA Medical Center, Mather, CA.

To date, he has published over 506 original papers and invited reviews in the areas of diabetes, atherosclerosis, lipid metabolism, nutrition and vascular biology and has a H-Index of 73. He has received numerous awards for his research and has served on Editorial Boards of numerous journals including the American Journal of Clinical Nutrition, Journal of Molecular and Cellular Cardiology, Journal of Diabetes and Its Complications, and Journal of Clinical Endocrinology and Metabolism. Dr. Jialal served as Section Editor of AJCP for Clinical Chemistry, Associate Editor , Atherosclerosis, and Editor-in-Chief of Metabolic Syndrome & Related Disorders. He also has a long standing interest in hyperlipidemia and diabetes. His major research interest is in the role of inflammation in atherosclerosis, metabolic syndrome, and understanding the pathobiology of diabetic vasculopathies. His research has been funded over the years by the National Institutes of Health (NIH), American Diabetes Association, Juvenile Diabetes Research Foundation, and American Heart Association. He serves on the Grant Review Panels of the ADA and JDRF, as well as the National Institutes of Health.

Dr. Jialal has received numerous awards for his work including the VERIS Award for Nutrition Research; the Centrum Center Science for Nutrition Award, American Society of Nutritional Sciences; the International Hermes Prize for Vitamin Research; the Bennie Zak Award for Outstanding Research, Lipids and Lipoproteins Division, AACC; the Grace Goldsmith Award from the American College of Nutrition; the NIH Mid-Career Investigator Award in Patient Oriented Research, the Distinguished Scientist Award from the National Academy of Clinical Biochemistry, Recipient of the Outstanding Contributions to Clinical Chemistry in a Selected Area of Research Award of the American Association for Clinical Chemistry, the Linus Pauling Award, American College for Advancement in Medicine; Philip Levine Award, American Society of Clinical Pathology, Cooper Award, Lipoprotein and Vascular Diseases Division, AACC, Joliff Award, Division of Clinical and Diagnostic Immunology, AACC and the Garry-Labbe Award for his outstanding contributions in Nutrition , AACC and Diplomate, American Board of Clinical Lipidology . He has been listed Best Doctors in America for 8 years .He has been recipient of the Pathology Teaching Award from the residents at both UT Southwestern and UCDMC.


Ruth Vinall, PhDRuth Vinall, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: (916) 686-8532
Fax: (916) 686-8142

Ruth Vinall is an Associate Professor in the Department of Pharmaceutical & Biomedical Sciences at California Northstate University College of Pharmacy (CNUCOP). She received her Ph.D. from Cardiff University, U.K., Department of Anatomy. After receiving her doctoral degree, Dr. Vinall worked as a postdoctoral researcher at UC Davis Medical Center. In 2009 Dr. Vinall completed a NIH K30 program-funded M.A.S. degree in Clinical Research at UC Davis and was subsequently appointed as a research faculty in the Department of Urology. During her time at UC Davis Dr. Vinall supervised multiple undergraduate, graduate and medical students, and in 2009 and 2010 was awarded Outstanding Mentor awards for her work with the UC Davis CURE program.

Dr. Vinall’s research focuses on prostate and bladder cancer research. She recently received an NIH R15 grant entitled ‘Role of the AR-Nrdp-1-ErbB3 axis in mediating prostate cancer health disparities’. In addition to prostate cancer health disparities research, she is interested in determining mechanisms of chemoresistance and identifying biomarkers that can predict patient’s response to chemotherapy, a primary focus is miRNA research.

Research Interest:
SProstate and bladder cancer
MiRNA
Chemoresistance
Cancer health disparities

Selected Publications (out of a total of 20):

  1. Ruth L. Vinall, Clifford G. Tepper, Alexandra A. Z. Ripoll, Regina F. Gandour- Edwards, Blythe P. Durbin-Johnson, Stanley A. Yap, Paramita M. Ghosh and Ralph W. deVere White. Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy. Genes&Cancer, Volume 7 (3-4), March 2016.
  2. Wang S, Zhang H, Scharadin TM, Zimmermann M, Hu B, Pan AW, Vinall R, Lin TY, Cimino G, Chain P, Vuyisich M, Gleasner C, Mcmurry K, Malfatti M, Turteltaub K, de Vere White R, Pan CX, Henderson PT. Molecular dissection of induced platinum resistance through functional and gene expression analysis in a cell culture model of bladder cancer. 2016. PLoS One. 11(1): 1-18.
  3. Benjamin A. Mooso, Ruth L. Vinall, Maria Mudryj, Stanley A. Yap, Ralph W. deVere White, Paramita M. Ghosh. Therapeutic Regimens for Muscle-Invasive Bladder Cancer with EGFR Family Inhibitors: A Review of Clinical Trials and Molecular Evidence. Journal of Urology, 5347(14)04269-4.
  4. Vinall RL, Kent MS, deVere White RW. Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma. Am J Vet Res. 2012 Oct;73(10):1626-33.
  5. Mooso BA, Vinall RL, Tepper CG, Savoy RM, Cheung JP, Singh S, Siddiqui S, Wang Y, Bedolla RG, Martinez A, Mudryj M, Kung HJ, Devere White RW, Ghosh PM. Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. Endocr Relat Cancer. 2012 Nov 9;19(6):759-77.
  6. Vinall, R., Chen, J., Hubbard, N., Sulaimon, S., deVere White, R., and Borowsky, A. Evidence for an alternate molecular progression in prostate cancer. Disease Models & Mechanisms. 2012 Nov;5(6):914-20
  7. Vinall, RL., Z.Ripoll, Wang, S., Pan, C-X. and deVere White, R. MiR-34a Chemo-Sensitizes Bladder Cancer Cells to Cisplatin Treatment Regardless of p53-Rb Pathway Status. Int J Cancer, 2012 Jun 1;130(11):2526-38.
  8. Vinall, R., Mahaffey, C., Davis, R., Luo, Z., Gandour-Edwards, R., Ghosh, P., Tepper, C., deVere White, R. Dual blockade of PKA and NF-kB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. Horm. Cancer. 2011. 2(4):224-38.
  9. Liu S, Vinall RL., Tepper C, Shi XB, Xue LR, Ma AH, Wang LY, Fitzgerald LD, Wu Z, Gandour-Edwards R, deVere White RW, Kung HJ. Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. Oncogene. 2008 Jan 17;27(4):499-505.
  10. Vinall, RL., Hwa, K., Ghosh, P., Pan, CX., Lara, PN., deVere White, RW. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin Cancer Res. 2007 Oct 15;13(20):6204-16.
  11. Tepper CG, Vinall RL, Wee CB, Xue L, Shi X-B, Burich R, Mack PC, and deVere White RW. GCP-mediated Growth Inhibition and Apoptosis of Prostate Cancer Cells Via Androgen Receptor-dependent and -Independent Mechanisms. 2007. Prostate. 2007 Apr 1;67(5):521-35.
  12. Vinall, RL, Tepper CG, Xue, L.A., Shi XB, deVere White RW. The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene, 25:2082-2093, 2006.

Hatem Elshabrawy, PharmBS, PhDHatem Elshabrawy, PharmBS, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Office Phone: (916) 686-8024

Research Interest: Dr. Hatem Elshabrawy is an Assistant professor of Immunology and Pharmaceutical Sciences at California Northstate University College of Pharmacy since July 2017. In 2003, he received his B.S. in Pharmacy from Cairo University, Egypt. After earning his B.S., Dr. Elshabrawy taught pharmacy students classes in Immunology, Virology, General and Medical Microbiology, Molecular Biology, Cell Biology, Pharmacology, and Medicinal Chemistry (2004-2008). Dr. Elshabrawy got admitted to University of Illinois at Chicago Ph.D. program of Microbiology and Immunology with a full scholarship in the fall of 2008. He earned his Ph.D. in Microbiology and Immunology in 2012, and his Ph.D. research resulted in the development of monoclonal antibodies and small molecules as broad-spectrum therapeutics for a wide range of viral infections including SARS-CoV and Ebola virus. During his postdoctoral studies at the University of Illinois at Chicago (2015-2017), Dr. Elshabrawy studied the pathogenesis of rheumatoid arthritis (RA) and he developed a monoclonal antibody and small molecules against a specific target in RA . Dr. Elshabrawy’s current research projects are investigating the role of novel receptors in the polarization of RA macrophages into proinflammatory M1 macrophages, and the development of small molecules or monoclonal antibodies that can be used as drugs to ameliorate RA. His research efforts led to 13 original research articles, a patent, and several abstracts in international research conferences. Dr. Elshabrawy serves as an Editor and scientific reviewer for many peer-reviewed journals including Journal of Infectious Diseases, Journal of Leukocyte Biology, Scientific Reports, PLOS ONE, Molecular Medicine, and others.

Course Taught: Advance Topics in Immunology

Selected Publications:

  1. IL-11 facilitates a novel connection between RA joint fibroblasts and endothelial cells. Hatem A. Elshabrawy, Michael V. Volin, Abdul B. Essani, Zhenlong Chen, Iain B. McInnes, K. Van Raemdonck, K. Palasiewicz, Shiva Arami, M. Gonzalez, HM Ashour, SJ Kim, G. Zhou, DA Fox, and Shiva Shahrara. Angiogenesis, January 2018.
  2. Differential impact of obesity on the pathogenesis of RA or preclinical models is contingent on the disease status. Seung-jae Kim, Zhenlong Chen, Abdul B. Essani, Hatem A. Elshabrawy, Michael V. Volin, Giamila Fantuzzi, Iain B. McInnes, Joshua F. Baker, Patricia Finn, George Kondos, Suncica Volkov, William Swedler, and Shiva Shahrara. Annals of Rheumatic Diseases, November 2016 (Highlighted in the issue for its significance).
  3. TLRs, future potential therapeutic target for RA. Hatem A. Elshabrawy, Abdul Essani, Zoltán Szekanecz, and Shiva Shahrara. Autoimmunity reviews, December 2016.
  4. Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice. Christine Haddad, Palash Bhattacharya, Khaled Alharshawi, Alejandra Marinelarena , Prabhakaran Kumar, Osama El-Sayed, Hatem A. Elshabrawy, Alan L. Epstein, Bellur S. Prabhakar. Autoimmunity, May 2016.
  5. Identification of a Novel Toll-like Receptor 7 Endogenous Ligand in Rheumatoid Arthritis Synovial Fluid That Can Provoke Arthritic Joint Inflammation. Seung-jae Kim, Zhenlong Chen, Abdul Essani, Hatem A. Elshabrawy, Michael V. Volin, Suncica Volkov, William Swedler, Shiva Arami, Nadera Sweiss, Shiva Shahrara. Arthritis and Rheumatology, April 2016.
  6. The pathogenic role of angiogenesis in rheumatoid arthritis. Hatem A. Elshabrawy, Zhenlong Chen, Michael V. Volin, Shalini Ravella, Shanti Virupannavar, and Shiva Shahrara. Angiogenesis, July 2015.
  7. Ebola virus outbreak, updates on current therapeutic strategies. Hatem A. Elshabrawy, and Bellur S. Prabhakar. Reviews in Medical Virology, July 2015.
  8. A Podocyte Automated Screening Assay Identifies Protective Small Molecules. Ha Won Lee, Samia Khan, Mohd Hafeez Faridi, Changli Wei, Nicholas J.Tardi, Mehmet Altintas, Hatem A. Elshabrawy, Steeve Mangos, Quick K, Sanja Sever, Jochen Reiser, and Vineet Gupta. Journal of the American Society of Nephrology, April 2015.

Lakshmi Chaturvedi, PhDLakshmi Chaturvedi, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Office Phone: (916) 686-8559
Fax: (916) 686-8143

Dr. Lakshmi Shankar Chaturvedi (Shankar) is the Associate professor in the Department of Pharmaceutical and Biomedical Sciences-College of Pharmacy (CNUCOP) and in the Department of Basic Sciences-College of Medicine (CNUCOM) at California Northstate University (CNSU). He is a Director of Research at San Joaquin General Hospital (SJGH), French Camp, CA. Prior to joining CNSU/SJGH, he was an associate professor in the Departments of Surgery, Pathology and Biomedical Sciences at University of North Dakota School of Medicine and Health Sciences (UND-SMHS), Grand Forks, ND. He obtained his Bachelor of Science (B.Sc.) degree in Biology from University of Allahabad, Allahabad in Uttar Pradesh (UP), India and Master of Science (M.Sc.) degree in Biotechnology from Guru Nanak Dev University, Amritsar in Punjab, India. He obtained his Doctor of Philosophy (PhD) from Sanjay Gandhi Post-Graduate Institute of Medical Sciences (SGPGIMS), UP, India in Medical Genetics. His PhD thesis work is entitled “Carrier analysis, prenatal diagnosis and point mutation studies in Duchenne/Becker muscular dystrophy (D/BMD)” families. During his PhD research work, he identified of a new rare point mutation in the human dystrophin gene that has been included in the rare mutation/ polymorphism category in Duchenne/Becker Muscular Dystrophy database/Leiden muscular Web page (www.dmd.nl).

Dr. Chaturvedi has an active research group. He supervised medical students, graduate, research associates and junior faculties at Henry Ford Hospital, Wayne State University in Detroit, Michigan State University in East Lansing, MI and University of North Dakota, Grand Forks, ND on multiple research projects related cell-proliferation, apoptosis, migration, differentiation and cell signaling in the area of breast, colon, intestine, lung, kidney, prostate, and microglial cell-culture system. He has vast experience in handling various pharmacological inhibitor/activators and short interfering RNA (siRNAs) and nanoparticles and their application in biomedical research. Dr. Chaturvedi has taught different courses of medical genetics like clinical genetics, biochemical genetics, molecular genetics, genetic counseling, mutational analysis, and cell signaling. He was co-chair of the hiring committee for Junior Faculties, research associate and post-doctoral fellow in the department of Surgery at UND-SMHS. He has served as a chair for poster session for graduate/post-graduate, medical student and research associates at UND-SMHS. He has also served as a Judge for poster sessions for annual meetings of North Dakota State Science & Engineering Fair (NDSSEF), Michigan State University-College of Human Medicine and Wayne State University-School of Medicine on Research day presentations.

Research Interest: His research focuses on cancer and cell signaling, mitosis, apoptosis, wound healing, differentiation, nanoparticles and drug targets in biomedical research and healthcare. His research interest includes assessment of learning and teaching.

Course taught: Pharmacogenomics and Genetics

Selected Publications (From 46 papers; www.researchgate.net/profile/Lakshmi_Chaturvedi/contributions)

  1. Basson, M.D., Wang, Q., Chaturvedi, L.S., Dekrey, E, Sun, K., Kuhn, L., Kovalenko, P., and Kiupel, M. et al. Schlafen 12 drives human enterocyte differentiation via interaction with Serpin B12 and deubiquitylases. Cell Physiol Biochem, 2018.
  2. Vyas D, Lopez-Hisijos N, Shah P, Deshpande KS, Basson MD, Vyas A, Chaturvedi LS. A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells. J Nanosci Nanotechnol.17(1):175-85, 2017.
  3. Katkoori, V., Manne, U., Chaturvedi L., Basson, M., Haan, P., Coffey, D., and Bumpers, H. Functional consequence of the p53 codon 72 polymorphism in Colorectal Cancer. Oncotarget, 8(44):76574-76586, 2017.
  4. Vyas D., Deshpande, K., Chaturvedi, L., Gieric, L., and Ching, K. Rapid Extensive Recurrence of Triple Negative Breast Cancer: Are Both Therapy and Cancer Biology the Culprit? J Clin Med Res, 8(2):162-167, 2016.
  5. Vyas, D., Lopez-Hisijos, L., Gandhi, S., El-Dakdouki, M., Basson, M.D., Walsh, M., Huang, X., Vyas, A and Chaturvedi, L.S. Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells. Journal of Nanoscience and Nanotechnology, 15(9):6413-6422, 2015.
  6. Walsh, M.F., Hermann, R., Lee, J.H., Chaturvedi, L.S. and Basson, M.D. Schlafen 3 Mediates the Differentiating Effects of Cdx2 in Rat IEC-Cdx2L1 Enterocytes. J Invest Surg. 28(4):202-207, 2015.
  7. Chaturvedi, L., Sun, K., Walsh, M., Kuhn, L.A., and Basson, M.D. The P- loop region of Schlafen 3 acts within cytosol to induce differentiation of human Caco-2 intestinal epithelial cells. BBA Molecular Cell Research Biochim Biophys Acta.1843(12):3029-37, 2014.
  8. Chaturvedi, L.S. and Basson, M.D. The glucagon-like peptide-2 (GLP-2) analog teduglutide stimulates proliferation but reduces differentiation in human Caco-2 intestinal epithelial cells. JAMA Surg, 148(11):1037-42, 2013.
  9. Chaturvedi, L.S., Marsh, H. M., Shang, X., Zheng, Y., and Basson, M.D. Repetitive deformation activates FAK and ERK mitogenic signals in human Caco-2 intestinal epithelial cells through Src and Rac1. J Biol Chem. 2007 282(1):14-28, 2006.

Tibebe Woldemariam, PharmBS, PhDTibebe Woldemariam, PharmBS, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: (916) 686-8098

Tibebe Woldemariam is Associate Professor at the California Northstate University College of Pharmacy. He received his B.S. in Pharmacy and Ph.D. in Pharmaceutical Chemistry from Addis Ababa University, Ethiopia and University of Bradford, England, respectively. Before joining CNUCOP, he worked as a Senior Research Chemist at Biotechnology Companies in Massachusetts and California, where he was responsible for the isolation and characterization of bioactive molecules from diverse microbial, plants and plants tissue culture extracts. He began his academic career at King’s College London, before he joined California Northstate University College of Pharmacy as an Assistant Professor in 2008. In addition to his regular duties as an associate professor, Dr. Woldemariam works as a community pharmacist to expand his knowledge beyond Medicinal Chemistry and help precept students when needed.

Research Interest:
Sunscreen
Inflammatory Bowel Disease
Cancer & Chemotherapy

Course Taught: Techniques in Pharmaceutical Sciences

Selected publications:

  1. Tibebe Woldemariam. Poster presentation entitled ‘Natural Products as a Source of Anti-Inflammatory Agents for Treating Inflammatory Bowel Disease’ at 55th Annual Meeting of the Phytochemical Society of North America, University of California at Davis, Aug. 6 – 10, 2016.
  2. Tibebe Woldemariam, George Talbott, and Leo R., Fitzpatrick. Fitzpatrick. Poster presentation entitled ‘Enrichment and Purification of Flavonoids from The Alcoholic Extract Of Althaea Officinalis Root’ at 55th Annual Meeting of the Phytochemical Society of North America, University of California at Davis, Aug. 6 – 10, 2016.
  3. Tibebe Woldemariam∗ and Jake Van Winkle. In Vitro Hypoglycemic Effect of Salvia hispanica Using a Yeast Glucose Uptake Model. Journal of Pharmaceutical Sciences and Pharmacology Vol. 2, 1–4, 2015.
  4. Woldemariam TZ, Malekakhlagh A, Bett C, Pearson D. Evaluation of the anti-tumor activity of selected herbs and spices, Journal of Pharmaceutical Sciences and Pharmacology; 2014; 1, 1–8. www.aspbs.com/jpsp.
  5. Xiaodong Feng, Amie Cai, Kevin Dong, Wendy Chaing, Max Feng, Nilesh S. Bhutada, John Inciardi, Tibebe Woldemariam (2013) ‘Assessing Pancreatic Cancer Risk Associated with Dipeptidyl Peptidase 4 Inhibitors: Assessing FDA Adverse Event Reporting System (FEARS)’ . J. Pharmacovigilance, 1:3. pp 1-7. http://dx.doi.org/10.4172/2329-6887.1000110.
  6. Woldemariam, T.Z. et al., (2012) ‘Pharmacogenetics: Would it be a reason for the lack of potency and intrinsic toxicity of several natural medicines?’ J. Proteomics & Bioinformatics. Volume 5, issue 6, p83.

Leo Fitzpatrick, PhDLeo Fitzpatrick, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: (916) 686-8364

Leo Fitzpatrick is the Assistant Dean of Research at the California Northstate University College of Pharmacy. He began his scientific career, by doing a post-doctoral fellowship at the University of Texas Medical School (Houston). Subsequently, Dr. Fitzpatrick was involved in drug discovery and development at three pharmaceutical companies. At Otsuka Pharmaceutical Inc. (Maryland Research Institute), he contributed to the development of Tetomilast, which advanced into phase 3 clinical trials for Inflammatory Bowel Disease (IBD). Subsequently, Dr. Fitzpatrick began a 10 year (2003-2013) faculty position at the Penn State College of Medicine (Hershey, PA). While at Penn State, he continued ongoing research related to IBD, infectious colitis and arthritis. His research collaborations resulted in the funding of 15 academic-related grants/contracts with pharmaceutical/biotechnology companies. While at Penn State, Dr. Fitzpatrick collaborated with a German company (4SC AG). This collaboration contributed to the development of Vidofludimus (a novel immunosuppressive drug), which has entered phase 2 clinical trials for IBD in Europe. He has served on the editorial board of World Journal of Gastrointestinal PathoPhysiology, and Pharmacy & Pharmacology International Journal. Dr. Fitzpatrick has also served on the scientific advisory board for Baxter Health Care. His research interests are in IBD, Infectious Colitis and Rheumatoid Arthritis. He has published 54 original research articles, as well as approximately 70 conference-related abstracts. Dr. Fitzpatrick has taught graduate and medical student classes in pharmacology, immunology and GI PBL at the Penn State College of Medicine, as well as classes in pathophysiology and immunology at the California Northstate University College of Pharmacy.

Research Interest:
Inflammatory Bowel Disease
Rheumatoid Arthritis
Infectious Colitis

Courses taught: Journal club and Graduate Seminar

Selected publications:

  1. LR Fitzpatrick and T Woldemariam (2016). Small Molecules to Treat Inflammatory Bowel Disease. In: Comprehensive Medicinal Chemistry III, Volume 5: Cancer, Immunology and Inflammation, and Infectious Disease (L. Lombardo, editor). Elsevier Inc., Accepted for Publication.
  2. LR Fitzpatrick, E Stonesifer, JS Small, K Liby (2014). The Synthetic Triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and Improves DSSS-Induced Colitis in Mice. Inflammopharmacology, 22:341- 349.
  3. LR Fitzpatrick (2012). Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis. International Journal of Inflammation, available online, PMID: 22506136.
  4. LR Fitzpatrick, JS Small, R Doblhofer, A Ammendola (2012). Vidofludimus inhibits colonic IL-17 and improves hapten-induced colitis in rats by a unique dual mode of action. JPET 342:850-860.

Linh Ho, PharmBS, PhDLinh Ho, PharmBS, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: (916) 686-7370
Fax: (916) 686-8142

Linh Ho is an Assistant Professor in the Department of Pharmaceutical & Biomedical Sciences at the California Northstate University College of Pharmacy. She received her B.S. in Pharmacy and M.S. in Pharmaceutical Sciences from University of Medicine and Pharmacy HCMC, and a Ph.D. in Chemistry and Chemical Biology (Pharmacology) from University of California San Francisco (UCSF). Prior to joining California Northstate University, Dr. Ho continued her post-doctoral research at UCSF in regulation of mesenchymal stem cell fate, adipogenesis, and metabolism homeostasis of mitochondrial Sirtuin-3. She has been also working on molecular mechanism of mitochondrial disease (MELAS). Dr. Ho’s research focuses on mitochondrial Sirtuins and signalling pathway in metabolic abnormalities, especially type II diabetes. She is exploring Anti-diabetogenic Role of a Sirtuin-3-Adipokines (Adiponectin) Axis in Adipocytes.

Research Interest:
Diabetes and metabolic abnormalities
Mitochondrial Sirtuins and Mitochondrial diseases

Selected Publications:

  1. Linh Ho, Theresa Roth, Yong Pan, Eric M. Verdin, Edward C. Hsiao, Robert A. Nissenson. Sirtuin-3 promotes bone loss in aging male mice. Under reviewing for submitting to Endocrinology.
  2. Marcia J. Abbott, Theresa M. Roth, Linh Ho, Liping Wang, Dylan O’Carroll, Robert A. Nissenson. Negative Skeletal Effects of Locally Produced Adiponectin. PLoS One. 2015; 10(7):e0134290.
  3. Linh Ho, Allen Sam Titus, Philipp Gut, Wei Lin, Mingjian Fei, Kushal Banerjee, Asish K. Saha, Ken Nakamura, Eric Verdin, Ullas Kolthur Seetharam. SIRT4 regulates ATP homeostasis and mediates a retrograde signaling via AMPK. Aging (Albany NY). Nov 2013; 5(11):835–849
  4. Wirth M, Karaca S, Wenzel D, Linh Ho, Tishkoff D, Lombard DB, Verdin E, Urlaub H, Jedrusik-Bode M, Fischle W. Mitochondrial SIRT4-type proteins in Caenorhabditis elegans and mammals interact with pyruvate carboxylase and other acetylated biotin-dependent carboxylases. Mitochondrion. 2013 Feb 21.
  5. He W, Newman JC, Wang MZ, Linh Ho, Verdin E. Mitochondrial sirtuins: regulators of protein acylation and metabolism. Trends Endocrinol Metab. 2012 Sep; 23(9):467-76.
  6. Peng C, Lu Z, Xie Z, Cheng Z, Chen Y, Tan M, Luo H, Zhang Y, He W, Yang K, Zwaans BM, Tishkoff D, Linh Ho, Lombard D, He TC, Dai J, Verdin E, Ye Y, Zhao Y. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol Cell Proteomics. 2011 Dec; 10(12):M111.012658.
  7. Shimazu T, Hirschey MD, Huang JY, Linh Ho, Verdin E. Acetate metabolism and aging: An emerging connection. Mech Ageing Dev. 2010 Jul-Aug; 131(7-8):511-6.
  8. Huang JY, Hirschey MD, Shimazu T, Linh Ho, Verdin E. Mitochondrial sirtuins. Biochim Biophys Acta. 2010 Aug; 1804(8):1645-51.
  9. Mark Albano, Wiep Klaas Smits, Linh Ho, Barbara Kraigher, Oscar Kuipers and David Dubnau. The Rok protein of Bacillus subtilis represses genes for cell surface and extracellular functions. J. Bacteriol, Vol.187, No. 6, Mar. 2005, p. 2010-2019.

Uyen Minh Le, PharmBS, PhDUyen Minh Le, PharmBS, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: (916) 686-8552

Dr. Le is the chair and associate professor in the Department of Pharmaceutical and Biomedical Sciences at California Northstate University College of Pharmacy (CNUCOP). Prior to joining CNUCOP, she was an associate professor at Sullivan University College of Pharmacy (SUCOP). She got her B.S. in Pharmacy and M.S. in Pharmaceutical Sciences, both from Ho Chi Minh City University of Medicine and Pharmacy. She obtained her Ph.D. from Oregon State University College of Pharmacy, major in pharmaceutical sciences and minor in statistics. Dr. Le has taught different courses of physical pharmacy, pharmaceutics, biopharmaceutics, pharmacokinetics, and pharmaceutical compounding. Under her coaching, SUCOP team won the champion title at the 2016 National Student Pharmacist Compounding Competition.

She has served as the co-chair of the assessment committee in the AACP Laboratory Instructors Special Interest Group in 2017-2018. She was also the advisor to the AAPS student chapter and served as member of committees such as graduate, accreditation, admission, curriculum, co-curriculum, planning and assessment, promotion, and faculty development.

Dr. Le has published various peer-reviewed journal articles and book chapters as well as presented at different national/international conferences. Her laboratory research focuses on drug delivery, drug target, biomedical modeling and simulation, and data-mining in healthcare. Her pedagogical research interest includes assessment of learning and teaching.

Research Interest:
Drug delivery/Drug target
Biomedical modeling and simulation
Datamining in healthcare
Pharmacy education assessment

Selected Publications:

  1. B Loo, H Nguyen, UM Le. Antioxidant nutraceuticals for skin care. Antioxidant Nutraceuticals: Preventive and Healthcare Application. CRC Press. 2017
  2. UM Le, K Spio, G Pillai. Current pharmaceutical compounding for neuropathic pain. BAOJ Pharmaceutical Sciences. 2016; 2(2): 22-25
  3. UM Le, Y Pathak, HT Tran. Methods for polymeric nanoparticle conjugation to monoclonal antibody. Antibody Mediated Drug Delivery Systems: Concepts, Technology, and Applications. John Wiley & Sons. 2012; 1: 351-364.
  4. UM Le, Y Pathak. Nutraceuticals: Advancing in a right direction. Handbook of Nutraceuticals. CRC Press. 2011; 2:1-14.
  5. GLM Bui, UM Le, HT Tran, Y Pathak. Delivery of herbal extracts and compound using nanotechnology. Advances in Nanotechnology & Application. Centera. 2010; 2: 121-136.
  6. UM Le, HT Tran, Y Pathak. Nanoparticles in transdermal drug delivery. Advances in Nanotechnology & Application. Centera. 2009; 1: 146-155.
  7. UM Le, DG Kaurin, BR Sloat, ZR Cui. Localized irradiation of tumors prior to synthetic dsRNA therapy enhanced the resultant anti-tumor activity. Radiother Oncol. 2009 Feb; 90(2):273-9.
  8. UM Le, DS Shaker, BR Sloat, ZR Cui. Thermo-sensitive polymeric gel containing a gadolinium (Gd) compound encapsulated into liposomes significantly extended the retention of the Gd in tumors. Drug Development and Industrial Pharmacy. 2008; 34(4):413-8.
  9. UM Le, N Yanasarn, CV Loehr, KA Fischer, ZR Cui. Tumor chemo-immunotherapy using gemcitabine and a synthetic dsRNA. Cancer Biology & Therapy, 2008; 7(3):440-7.
  10. BR Sloat, DS Shaker, UM Le, ZR Cui. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens. FEMS Immunology & Med Microbiology. 2008; 52(2):169-79.
  11. DS Shaker, BR Sloat, UM Le, CV Loehr, N Yanasarn, KA Fischer, ZR Cui. Immunization by applying DNA vaccine onto a skin area where the hair follicles are induced into anagen-onset stage. Molecular Therapy. 15(11):2037-43, 2007.
  12. ZR Cui, UM Le, F Qiu, DS Shaker. Learning from viruses: the necrotic bodies of tumor cells with intracellular synthetic dsRNA induced strong anti-tumor immune responses. Pharmaceutical Research. 24(9):1645-52, 2007.
  13. UM Le, ZR Cui. Biodistribution of Gadolinium (Gd) encapsulated in long-circulating liposomes in tumor-bearing mice: effects of tumor type, dosing schedule, and tumor size on the uptake of Gd by tumors. International Journal of Pharmaceutics. 320(1-2):96-103, 2006.
  14. UM Le, ZR Cui. Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy. International Journal of Pharmaceutics. 312(1-2):105-12, 2006.

Suzanne Clark, PhDSuzanne Clark, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: (916) 686-7376
Fax: (916) 686-8142

Suzanne Clark, RPh, PhD, is an Associate Professor of Pharmacology at California Northstate University College of Pharmacy and Vice-Chair of the Department of Pharmaceutical & Biomedical Sciences. She received her B.S. from the University of Iowa, her B.S. in Pharmacy from the University of Wyoming, and her Ph.D. in Pharmacology from Duke University. Her graduate research focused on in vitro models of epilepsy, anticonvulsant drug development, and glutamatergic/GABAergic processes. Her post-doctoral research at the Durham Veterans Administration Medical Center/Duke University Medical Center focused on epilepsy and military occupational exposures to neurotoxins and their underlying neurotoxic mechanisms. After completing additional postdoctoral work on AMPA receptors and epilepsy at Colorado State University, she moved to the University of Wyoming School of Pharmacy, where she taught Pathophysiology to PharmD and Nursing students for nine years. She moved to the CNU College of Pharmacy in 2014, where she teaches pharmacology and pathophysiology of the nervous system. She also worked as a hospital and community pharmacist in Colorado and as a specialist at the Duke Poison Control Center. Her interests include neuropharmacology, occupational and environmental public health, pharmacy education, and team-based learning. She was a founding member of the new Pharmacy Special Primary Interest Group in the American Public Health Association. She has included PharmD and Nursing students in many aspects her teaching, research, and service, and has facilitated opportunities for students to receive institutional, regional and national awards, as well as helping them pursue post-graduate education, academic positions, and public health opportunities.

Selected Publications:

  1. DiPietro Mager NA, Ochs L, Ranelli PL, Kahaleh AA, Lahoz MR, Patel RV, Garza OW, Isaacs D, Clark S, Partners in Public Health: Public Health Collaborations With Schools of Pharmacy, Public Health Reports. 2017;132 1-6 DOI: 10.1177/0033354917698126
  2. Schilz JR, Reddy KJ, Nair S, Johnson TE, Tjalkens RB, Krueger KP, Clark S, Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability. J Vis Exp. 2015 Jun 21;(100):e52715. doi: 10.3791/52715.
  3. Witter, RZ, Tenney L, Clark S, Newman LS, Occupational Exposures in the Oil and Gas Extraction Industry: State of the Science and Research and Recommendations, American Journal of Industrial Medicine 2014 Mar 14. doi:10.1002/ajim.22316, PMID: 24634090
  4. Mahvan TD, Hornecker JR, Buckley WA, Clark S, The role of besifloxacin in the treatment of bacterial conjunctivitis., Ann Pharmacother. 2014 May;48(5):61625. doi: 10.1177/1060028014524175. Epub 2014 Feb 24.
  5. Leedy GM, Barrows LF, Clark S, Effects of social housing on hippocampal dendrites and behavior in ovariectomized rats. Brain Res Bulletin 3013; Mar;92:69-75 (Impact Factor: 2.818 (current 3/2013); 2.605 (5 year)
  6. Hua, Y, Clark, S, Ren, J, Nair, S., Molecular mechanisms of chromium in alleviating insulin resistance. J. Nutritional Biochem. 2012;23:313–319 (Review) (Impact Factor: 3.891 in 2011)
  7. White, A, Williams, PA, Hellier, JL, Clark, S, Dudek, FE, Staley, KJ, EEG spike activity precedes epilepsy after kainate-induced status epilepticus. Epilepsia, 2010;51(3):371-83 (PMID: 19845739) (Impact Factor 3.961 in 2011)
  8. Williams PA, White, AM, Clark S, Ferraro DJ, Swiercz W, Staley KJ, Dudek FE, Development of spontaneous recurrent seizures after kainate-induced status epilepticus, J. Neurosci 2009;29:2103-2112 (Impact Factor in 2011: 7.115)
  9. Wickenden, AD, Krajewski, JL, London, B, Wagoner, PK, Wilson, WA, Clark, S, Roeloffs, R, McNaughton-Smith, G, Rigdon, GC, ICA-27243: A novel, selective KCNQ2/Q3 potassium channel activator. Molec Pharmacol 2008;73:977-986. (Impact Factor: 4.883 in 2011)
  10. Grabenstatter, HL, S Clark, FE Dudek, Anticonvulsant effects of carbamazepine on spontaneous seizures in rats with kainate-induced epilepsy: comparison of intraperitoneal injections with drug-in-food protocols. Epilepsia 2007;(December) 48 (12), 2287–2295. (doi:10.1111/j.15281167.2007.01263.x) (Impact Factor: 3.961 in 2011)
  11. Williams P, White A, Ferraro D, Clark S, Staley K, Dudek FE, The use of radiotelemetry to evaluate electrographic seizures in rats with kainate-induced epilepsy. J Neurosci Methods. 2006;155:39-48.
  12. White AM, Williams PA, Ferraro DJ, Clark S, Kadam SD, Dudek FE, Staley KJ. Efficient unsupervised algorithms for the detection of seizures in continuous EEG recordings from rats after brain injury. J Neurosci Methods. 2006;152:255-66.
  13. Jin, R, Clark, S., Weeks, A.M., Dudman, J. T., Gouaux. E., Partin, K.M., Mechanism of positive allosteric modulators acting on AMPA receptors. J. Neurosci. 2005;25:9027-9036. (data-based)
  14. Kang-Park, M.-H., Sarda, M.A., Jones, K.H., Moore, S.D., Shenolikar, S., Clark, S., Wilson, W.A., (2003) Protein phosphatases mediate depotentiation induced by high-intensity theta-burst stimulation: a mechanism of seizure-induced amnesia?, J. Neurophysiology, Feb; 89(2): 684-90. (data-based)
  15. Leever J.D., Clark S., Weeks A.M., Partin K.M., (2003) Identification of a site in GluR1 and GluR2 that is important for modulation of deactivation and desensitization. Mol Pharmacol 64(1): 5-10. (data-based)

Philip Mack, PhDPhilip Mack, PhD

This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 916 686-7400

Research Interest: For the past twelve years, Dr. Mack has conducted basic and translational research, with an emphasis on lung cancer. His investigations include molecular and cellular effects of novel anticancer agents in lung cancer models. Dr. Mack is Director of the UC Davis Cancer Center Molecular Pharmacology shared resource, Director of Basic Sciences for the California Cancer Consortium and Associate Director of the Southwest Oncology Group Lung Translational Medicine Committee.

Selected Publications:

  1. El-Khoueiry, A. B., O’Donnell, R., Semrad, T. J., Mack, P., Blanchard, S., Bahary, N., ... Gandara, D. R. (2018). A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 1-7. DOI: 10.1007/s00280-018-3553-4
  2. Lara, P. N., Plets, M., Tangen, C., Gertz, E., Vogelzang, N. J., Hussain, M., ... Quinn, D. I. (2018). Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421. Cancer Treatment and Research Communications, 16, 18-23. DOI: 10.1016/j.ctarc.2018.04.005.
  3. Messing, E. M., Tangen, C. M., Lerner, S. P., Sahasrabudhe, D. M., Koppie, T. M., Wood, D. P., ... Thompson, I. M. (2018). Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence SWOG S0337 randomized clinical trial. JAMA - Journal of the American Medical Association, 319(18), 1880-1888. DOI: 10.1001/jama.2018.4657
  4. Herbst, R. S., Redman, M. W., Kim, E. S., Semrad, T. J., Bazhenova, L., Masters, G., ... Gandara, D. R. (2017). Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): A randomised, phase 3 study. The Lancet Oncology. DOI: 10.1016/S1470-2045(17)30694-0.
  5. Gandara, D. R., Riess, J. W., Kelly, K., Li, T., Mack, P. C., & Lara, P. N. (2017). Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non–Small-cell Lung Cancer. Clinical Lung Cancer, 18(1), 1-4. DOI: 10.1016/j.cllc.2016.12.011.
  6. Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., ... Omlin, A. (2017). Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology. DOI: 10.1016/j.eururo.2017.06.002.
  7. West, H. L., Moon, J., Wozniak, A. J., Mack, P., Hirsch, F. R., Bury, M. J., ... Gandara, D. R. (2017). Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clinical Lung Cancer. DOI: 10.1016/j.cllc.2017.06.016.